[Edaily Reporter Park Jeong-su] #Noeul, an AI-based blood and cancer diagnostics company, has been selected for a government export support program and is set to expand into global markets.

Noeul announced on the 10th that it has been selected for the “Global Strong SME 1000+ Project” in the growth enterprise category, organized by the Ministry of SMEs and Startups.
The Global Strong SME 1000+ Project is an initiative that identifies export-oriented small and medium-sized enterprises (SMEs) with high growth potential and provides them with various forms of support, including assistance with exports, financing, and research and development (R&D). Companies are selected based on a comprehensive evaluation of their ability to pioneer new markets and their potential for export growth.
With this selection, Noeul will receive various forms of support, including automatic eligibility for the Export Voucher Program, as well as policy financing, guarantees and insurance, preferential financial terms, and improved foreign exchange conditions. The company plans to use this support to strengthen its overseas marketing and export infrastructure.
Noeul has recently been expanding its overseas business, focusing on Europe and Latin America. It is strengthening cooperation with medical institutions and partner companies in European markets such as Germany and Romania, and is also exploring new business opportunities in Latin American countries such as Mexico and Panama.
In particular, it is reported that discussions are underway in Panama regarding the application of the AI diagnostic platform "miLab" to a national-level screening program.
Building on this selection, the company intends to leverage government support and its global network to intensify its push into the European and Latin American markets, while pursuing entry into additional countries and expanding strategic partnerships within the year.
"This selection is a testament to the innovation of our AI diagnostic technology and its global growth potential," said Lim Chan-yang, CEO of Noeul. "We will accelerate overseas sales growth and improve profitability based on the government’s support in exports, finance, and marketing."
Meanwhile, Noeul’s AI-based integrated diagnostic platform, miLab, is a solution that automates the entire diagnostic process—from the preprocessing of blood and tissue samples to digital imaging and AI analysis. According to the company, it significantly reduces the time required for manual microscopic examination and can provide sample analysis results in approximately 15 minutes on average.